Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, opakalim (BHV-7000), for refractory focal epilepsy. T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results